The overexpression of somatostatin receptor type 2 (SSTR2) is a property of various tumor types. Hybrid imaging utilizing [68Ga]1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid (DOTA) may improve the differentiation between tumor and healthy tissue. We conducted an experimental study on 47 anonymized patient cases including 30 meningiomas, 12 PitNET and 5 SBPGL. Four independent observers were instructed to contour the macroscopic tumor volume on planning MRI and then reassess their volumes with the additional information from DOTA-PET/CT. The conformity between observers and reference volumes was assessed. In total, 46 cases (97.9%) were DOTA-avid and included in the final analysis. In eight cases, PET/CT additional tumor volume was identified that was not detected by MRI; these PET/CT findings were potentially critical for the treatment plan in four cases. For meningiomas, the interobserver and observer to reference volume conformity indices were higher with PET/CT. For PitNET, the volumes had higher conformity between observers with MRI. With regard to SBGDL, no significant trend towards conformity with the addition of PET/CT information was observed. DOTA PET/CT supports accurate tumor recognition in meningioma and PitNET and is recommended in SSTR2-expressing tumors planned for treatment with highly conformal radiation.
2型生长抑素受体（SSTR2）的过度表达是多种肿瘤类型的特征。利用[68Ga]1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸（DOTA）的混合成像技术可提高肿瘤与正常组织的区分度。本研究对47例匿名患者病例（包括30例脑膜瘤、12例垂体神经内分泌肿瘤及5例副神经节瘤）进行了实验分析。四位独立观察者被要求在计划磁共振成像上勾画宏观肿瘤体积，随后结合DOTA-PET/CT提供的补充信息重新评估其勾画范围。通过对比观察者与参考体积的一致性进行评估。结果显示，46例（97.9%）患者存在DOTA摄取阳性并被纳入最终分析。其中8例通过PET/CT发现了磁共振成像未检测到的附加肿瘤体积，其中4例的PET/CT发现可能对治疗方案具有关键影响。对于脑膜瘤，结合PET/CT后观察者间及观察者与参考体积的一致性指数更高；对于垂体神经内分泌肿瘤，仅使用磁共振成像时观察者间的体积一致性更高；而副神经节瘤在增加PET/CT信息后未呈现显著的一致性趋势。研究表明，DOTA PET/CT能有效支持脑膜瘤与垂体神经内分泌肿瘤的精准识别，建议在计划采用高适形放疗的SSTR2表达肿瘤中推广应用。
肿瘤(癌症)患者之家